ArticleUrolithiasis2023
Can additional variables be used to predict stone-free rates following retrograde intrarenal surgery? Anticoagulants and parenchyma thickness: a detailed examination.
Article in Urolithiasis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Outcomes of retrograde intrarenal surgery in patients on anticoagulant or antiplatelet therapy: a multicenter matched case-control study by the RIRSearch Study Group.World journal of urology · 2025Article
- The impact of the ratio of renal parenchyma to renal volume on stone-free rates after RIRS: a retrospective study.Scientific reports · 2025Article
- Prediction of Residual Fragments After Flexible Ureteroscopic Stone Management: A Critical Evaluation Based on Patient- and Stone-Related Parameters.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this article is to identify the factors that predict the success of retrograde intrarenal surgery (RIRS), with a focus on the effect of renal parenchymal thickness and anticoagulant use on stone-free rates. From February 2014 to April 2022, cases of kidney stones treated with RIRS at our clinic were retrospectively screened. The study included 642 cases meeting all inclusion and exclusion criteria. The patients who were observed to be stone free after a single session of RIRS were assigned to Group F, while those with residual fragments were assigned to Group R. Group F comprised 472 patients, while Group R included 170 patients. The two groups have compared certain preoperative and postoperative laboratory and radiological parameters. The infundibulopelvic angle was significantly more acute in Group R (45.63 ± 16.25 vs. 49.28 ± 15.36, p = 0.011) while patients in Group F tended to have thicker parenchyma (27.39 ± 8.38 vs. 22.88 ± 5.56, p < 0.001). In our analysis of multivariate logistic regression, stone size (OR: 1.074, 1.037-1.113; p < 0.001), lower calyceal location (OR: 0.550, 95% CI 0.364-0.831; p = 0.005), multiple numbers of stones (OR 0.254, 95% CI 0.166-0.389; p = < 0.001), the value of parenchymal thickness (OR 0.911, 95% CI 0.882-0.941; p = < 0.001) and more importantly use of anticoagulants/antiplatelets (OR 0.557, 95% CI 0.333-0.933; p = 0.026) appeared to be independent predictors of stone-free status after RIRS. Further evaluation of the data revealed that the cut-off value of the renal parenchymal thickness for an effective stone-free status in a ROC curve analysis was 24.5 with 62.9% sensitivity and 56.8% specificity (area under curve value: 0.654 [95% CI 0.608-0.699, p < 0.001]). The endourologist may be able to make more informed decisions by evaluating renal parenchymal thickness in addition to patient-related factors like anticoagulant use, which we find significantly affects outcomes, along with the stone and renal anatomy-related factors.
Indexed as
Identifiers
36629914What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.